Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

医学 临床终点 黑色素瘤 内科学 皮疹 不利影响 临床试验 肿瘤科 实体瘤疗效评价标准 临床研究阶段 存活率 无进展生存期 代理终结点 外科 胃肠病学 总体生存率 癌症研究
作者
Richard D. Carvajal,Marcus Otho Butler,Alexander Noor Shoushtari,Jessica C. Hassel,Alexandra P. Ikeguchi,Leonel Fernando Hernandez-Aya,Paul Nathan,Omid Hamid,Josep Maria Piulats,Matthew J. Rioth,Douglas Buckner Johnson,Jason J. Luke,Enrique Espinosa,Serge Leyvraz,Laura E. Collins,Howard Goodall,Koustubh Ranade,Chris Holland,Shaad Essa Abdullah,Joseph J. Sacco
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:28 (11): 2364-2373 被引量:186
标识
DOI:10.1038/s41591-022-02015-7
摘要

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2-10%), the 1 year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8 months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
思源的应助被公冶白曼采纳,获得10
刚刚
NexusExplorer的应助被西柚采纳,获得10
刚刚
1秒前
科研通AI6.3的应助被wx采纳,获得10
1秒前
2秒前
小乖完成签到,获得积分20
3秒前
Uzer发布了新的文献求助10
4秒前
4秒前
勤奋柜子发布了新的文献求助30
4秒前
5秒前
既白发布了新的文献求助10
5秒前
5秒前
Wonder罗完成签到,获得积分10
5秒前
6秒前
6秒前
bulabulabu发布了新的文献求助10
6秒前
海底捞不动完成签到 ,获得积分10
6秒前
SciGPT的应助被甜甜的悲采纳,获得10
7秒前
清风完成签到,获得积分10
7秒前
8秒前
Akim的应助被大坤坤采纳,获得10
8秒前
8秒前
汉堡包的应助被qs采纳,获得10
10秒前
yjw0526发布了新的文献求助10
10秒前
默默初阳的应助被纯真若云采纳,获得20
10秒前
Leo发布了新的文献求助10
11秒前
海底捞不动关注了科研通微信公众号
11秒前
Ziezer发布了新的文献求助10
11秒前
12秒前
12秒前
丘比特的应助被两碗牛又面采纳,获得10
13秒前
66666完成签到,获得积分10
13秒前
upup完成签到,获得积分10
13秒前
懒狼狼的应助被王昊采纳,获得10
13秒前
13秒前
未炙完成签到 ,获得积分10
14秒前
14秒前
stone完成签到,获得积分10
15秒前
DYF发布了新的文献求助20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259